Etablissement Public De Sante Barthelemy Durand
- Address
- lock Available on a paid plan
Etablissement Public De Sante Barthelemy Durand - Mental Health Research Center
Etablissement Public De Sante Barthelemy Durand is a specialized psychiatric research institution focused on advancing treatment strategies for complex mental health disorders. The center demonstrates expertise in conducting rigorous clinical trials targeting both pediatric neurodevelopmental conditions and adult mood disorders, utilizing innovative pharmacological interventions and advanced neuroimaging techniques.
- Autism Spectrum Disorders in children and adolescents, with emphasis on social communication and interaction deficits
- Severe unipolar major depressive episodes requiring inpatient treatment
- Novel pharmacotherapies including histamine-based compounds and rapid-acting antidepressants
- Advanced neuroimaging studies utilizing PET-MRI to assess synaptic density and treatment response biomarkers
The research center's clinical trial portfolio reflects a commitment to addressing treatment-resistant psychiatric conditions through innovative methodologies. Their work encompasses both double-blind, placebo-controlled designs for evaluating emerging therapeutic agents and sophisticated imaging studies to understand the neurobiological mechanisms underlying clinical improvement. The center's dual focus on pediatric autism spectrum disorders and severe adult depression positions it as a comprehensive psychiatric research facility addressing critical unmet needs across the lifespan.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Etablissement Public De Sante Barthelemy Durand
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Intravenous Ketamine Versus Placebo as Adjunct to Venlafaxine in Severe Unipolar Major Depressive Episodes: A Double-Blind Randomized Controlled Trial | Assistance Publique Hopitaux De Paris | Phase III | Recruiting | Nov 2024 | — |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| (4R)-1-[(3-(11C)Methylpyridin-4-Yl)Methyl]-4-(3,4,5-Trifluorophenyl)Pyrrolidin-2-One | 1 | Unknown | 2024-11-20 | 2024-11-20 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.